All relevant data are within the manuscript.

Introduction {#sec005}
============

Quality indicators are useful objective tools to improve processes and services. In modern clinical medicine, laboratory tests play an important role in diagnosing, monitoring, and evaluating patient outcomes. Hence, the implementation of performance measurements to evaluate the pre-analytical, analytical and post-analytical stages of the total testing process is therefore needed to maximize the overall testing cycle and the quality of patient care \[[@pone.0230532.ref001]\].

Pre-analytical error and post-analytical error data are well documented. Occurrence of the errors at the pre- and post-analytical phases currently appears to be more vulnerable than the analytical phase \[[@pone.0230532.ref002]\]. Studies revealed that 46%--68.2% of laboratory errors predominated in the pre- analytical phase, and 18.5%--47% errors recorded in the post-analytical phase of the laboratory testing process \[[@pone.0230532.ref003]--[@pone.0230532.ref006]\].

The use of quality indicators that meet requirements for effectiveness and harmonization is an important quality improvement tool \[[@pone.0230532.ref007]\]. It can measure how well an organization meets the needs and requirements of users and the quality of all operational processes. Monitoring quality indicators in daily work can reduce laboratory errors and risk to patient safety by identifying problems in all phases of the laboratory process, allowing their correction \[[@pone.0230532.ref008]\].

Stock out of reagents, equipment down time, and sample rejection rates are common pre-analytical phase quality indicators, whereas the performance of proficiency testing (PT) in external quality assessment (EQA) program, internal quality control (IQC) and contamination or error rates are analytical phase indicators. Minimum recommended quality indicators for the post-analytical phase are turnaround time (TAT), the percentage of incorrect laboratory test reports, and notification of critical results \[[@pone.0230532.ref008], [@pone.0230532.ref009]\].

Laboratories should deliver accurate, reliable and timely results to customers. When the results are compromised in quality and/ or delayed, it could have an impact on patient management. As a result, the clinician may interpret the results as actionable which, in turn, can lead to unnecessary tests, procedures or treatments which may result in patient harm \[[@pone.0230532.ref010]\].

According to the World Health Organization (WHO), drug resistance TB and HIV are global challenges that need quality-assured laboratory tests for better treatment options and control of the burden \[[@pone.0230532.ref011]\]. In addition to the drug resistance burden, if there is poor quality laboratory service, the problem will be magnified.

In Ethiopia, where the estimated proportion of TB cases with multidrug resistant/ rifampicin-resistant tuberculosis (MDR/RR-TB) was16% among previously treated cases and reported a total of 428,472 HIV patients receiving antiretroviral therapy in 2018 \[[@pone.0230532.ref012], [@pone.0230532.ref013]\], laboratory tests are performed to control drug resistance and monitor disease progression. TB culture is performed to identify treatment failures, exposed infant diagnosis (EID) to identify HIV status in exposed infants, and viral load to monitor confirmed viral failure and estimate disease progression. However, the quality of critical aspects of pre-examination, examination and post-examination processes of TB and HIV related laboratory services have not been evaluated. Hence, this study aimed to use quality indicators to assess the performance of these four important tests, using nine months quality indicators data in the Amhara Public Health Institute (APHI).

Materials and methods {#sec006}
=====================

Study design {#sec007}
------------

A cross-sectional study was conducted to evaluate the continuous quality improvement of advanced TB and HIV related laboratory tests in APHI from 01 January to 30 September 2019.

Study setting {#sec008}
-------------

APHI is a government public health institute located in Bahir Dar town, Ethiopia at 11°60′N latitude and 37°37′E longitude. The institute has three main directorates (laboratory, public health emergency management, and research and technology transfer). It provides laboratory diagnostic services including TB (culture for treatment failure, and GeneXpert for rifampicin resistance), EID and viral load diagnosis to identify HIV status of infants and confirm antiretroviral failure, respectively. These TB and HIV related tests are requested from referring peripheral health facilities in Amhara region through a sample referral network. APHI is used as a reference testing center for more than 150 health facilities. All the laboratory tests investigated in APHI including HIV viral load, EID, TB culture and GeneXpert have been accredited by the Ethiopian National Accreditation Office (ENAO) in complying with the ISO 15189:2012 standard since October 2018 \[[@pone.0230532.ref014]\].

Data collection, and quality indicators and objective of each {#sec009}
-------------------------------------------------------------

In APHI, quality indicators were established to monitor the laboratory performance. EQA PT, contamination rate, error rate specimen rejection rate, TAT, IQC performance, stock out, service interruption and equipment down time were the APHI quality indicators ([Table 1](#pone.0230532.t001){ref-type="table"}). Each target was established by reviewing a minimum of 3 months of data at APHI and also reviewing international literature.

10.1371/journal.pone.0230532.t001

###### Quality indicators established in APHI, 01 January to 30 September 2019.

![](pone.0230532.t001){#pone.0230532.t001g}

  SN    Quality indicators     Target
  ----- ---------------------- ---------------------------------
  1\.   Equipment down time    Maintained within 5 days
  2\.   Stock outs             0%
  3\.   Specimen rejection     Less than 2%
  4\.   EQA PT performance     ≥80%
  5\.   TAT                    90% of tests within defined TAT
  6\.   IQC performance        100%
  7\.   Contamination rate     \<5% for TB culture
  8\.   Error rate             \<5% for GeneXpert
  9\.   Service interruption   0%

EQA: external quality assessment; IQC: internal quality control; PT: proficiency testing; SN: serial number; TAT: turnaround time; TB: tuberculosis.

All of the requested MDR TB, EID and viral load requested tests were included consecutively in the study. Data were collected using a record review of monthly quality indicator reports from January to September 2019. The established quality indicators at the pre-examination phase were equipment down time, stock out, test interruption, and specimen rejection rate.

Equipment down time was set as a quality indicator of APHI virology and bacteriology reference laboratories. All of the equipment should be repaired within 5 days if there is a failure. The equipment maintenance records for each of the following: Abbott 2000SP and Abbott 2000RT (used for extraction and detection of ribonucleic acid (RNA) of EID and HIV viral load); GeneXpert analyzer; and 35°C-37°C incubators (used for TB culture). No reagent stock out was set as a quality indicator by APHI. Reagent inventory records such as bin card, internal facility request and resupply form (IFRR), and report and requisition form (RRF) were reviewed to confirm the occurrence of stock outages.

An Excel database maintained in the central reception was used to review specimen rejections. Sputum for drug resistant tuberculosis (DRTB) /MDRTB, dried blood spot for EID and blood plasma for viral load samples were submitted at APHI central reception. The entire submitted patient samples were evaluated for sample quality based on pre-set sample rejection criteria. Sputum samples were rejected when there was labeling error, leaking specimen container, sample volume less than 2ml, sample received 5+ days after collection, use of the wrong container, specimen containing blood and food remnants or exposure to temperature exceeding 8^°^C. The plasma sample was rejected if samples were collected using the wrong container, not-centrifuged, hemolyzed, old (if it was delayed \>5 days after collection when transported to APHI at 2--8^°^C), insufficient volume, labeling error and if not transported below 8^°^C temperature. Dried blood spots (DBS) were rejected when there was hemolysis, insufficient volume of spots, clotting or labeling errors. Based on the APHI policy, rejected samples should be communicated to customers and another sample should be recollected for the requested test. The targeted specimen rejection rate was less than 2%.

Proficiency testing performance, contamination rate, error rates, and internal quality control were used for examination phase quality indicators. All of the evaluated tests (TB culture, GeneXpert, EID, and viral load) participated in proficiency testing from Oneworld Accuracy, which is an approved EQA PT provider. Panels of samples prepared by the PT provider were sent to APHI. In APHI, the PTs were analyzed as patient samples and results were submitted online on the Oneworld Accuracy website. Proficiency testing performance of 80% and above was the target goal \[[@pone.0230532.ref015]\]. Less than 5% target was set as the target goal for the contamination rate and error rate quality indicators by APHI. Applicable test records were reviewed to evaluate examination phase performances.

Moreover, turnaround time was a post-examination phase quality indicator that 90% of tests should be released within defined TAT: viral load = 10 days; EID = 10 days; TB negative culture = 48 days; TB positive culture = 64 days; and GeneXpert = 2 days. The TAT was calculated from login and log out of records of each test achieved at the excel database of the central reception. The TAT of each test was evaluated based on established targets of the institute ([Table 1](#pone.0230532.t001){ref-type="table"}).

Data review, cleaning and data analysis {#sec010}
---------------------------------------

The data were entered and analyzed using SPSS V20 software. Selected quality indicators were compared with the defined target and rated as good if complied or not good if not compliant with the established target.

Ethical consideration {#sec011}
---------------------

The data were not collected from patients directly since the specimens were collected from the peripheral health facilities and sent to the testing center through a referral network. Before data collection, ethics approval and official permission (Reference number: HRTT/03/139/2018) was obtained from the APHI research and technology transfer directorate to use patient records from the APHI excel database, quality indicator reports and record review of different quality related records in the laboratory. The Research and Technology Transfer Directorate waived the requirement for informed consent.

Results {#sec012}
=======

Test statistics and specimen rejection {#sec013}
--------------------------------------

In Amhara Public Health Institute, a total of 26,487 HIV and TB related test requests with samples were received from 01 January to 30 September 2019. Of which, 26372 (99.6%) had acceptable quality. Among the acceptable samples, 24517 (93.0%) were blood plasma samples for viral load, 862 (3.3%) were dried blood spot samples for EID, 694 (2.6%) were sputum samples for TB culture and 299 (1.1%) were sputum samples for TB GeneXpert tests ([Table 2](#pone.0230532.t002){ref-type="table"}).

10.1371/journal.pone.0230532.t002

###### Monthly test statistics, APHI, 01 January to 30 September 2019.
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  Tests          2019                                                                                                            
  -------------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ---------- ------------ ---------
  Viral load     2571       2710       3545       2018       2903       2304       3340       2630       2496       24517        106
  EID            85         179        0          0          271        87         85         90         65         862          0
  TB culture     77         69         87         77         91         32         122        54         85         694          8
  GeneXpert TB   4          7          9          60         47         25         56         45         46         299          1
  **Total**      **2737**   **2965**   **3641**   **2155**   **3312**   **2448**   **3603**   **2819**   **2692**   **26,372**   **115**

EID: exposed infant diagnosis; TB: tuberculosis.

A total of 115 were rejected from January to September 2019. The overall specimen rejection rate was 0.43% (115/26,487). Specifically, viral load, TB culture and TB GeneXpert specimens had 0.43% (106/24623), 1.14% (8/702) and 0.33% (1/300) rejection rates, respectively. High monthly sample rejection was documented for TB culture and viral load in September 2019 with 5.3% (5/95) and 2.4% (61/2557) rejection rates, respectively ([Table 3](#pone.0230532.t003){ref-type="table"}).

10.1371/journal.pone.0230532.t003

###### Specimen rejection rates of tests at APHI reference laboratories, January to September 2019.
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               2019                                                                                   
  ------------ ---------- --------- --------- ---- ---------- --- ----------- ----------- ----------- -------------
  Viral load   9(0.35%)   0         5(0.1%)   0    1(0.03%)   0   5 (0.15%)   25(0.94%)   61 (2.4%)   106 (0.43%)
  EID          0          0         ND        ND   0          0   0           0           0           0
  TB culture   1(1.3%)    2(2.8%)   0         0    0          0   0           0           5 (5.5%)    8(1.14%)
  GeneXpert    0          0         0         0    0          0   0           0           1(2.1%)     1(0.33%)

EID: exposed infant diagnosis; TB: tuberculosis; ND: not done.

Centrifugation problems (46.1% \[53/115\]) and the use of the wrong container (40.9% \[47/115\]) were the main reasons for specimen rejection. Viral load specimen rejections were due to centrifugation problems (53/106), use of wrong container (47/106), insufficient volume (5/106) and hemolysis (1/106). Old samples (5/8), use of a wrong container (1/8), insufficient volume (1/8) and uncontrolled temperature (1/8) were causes of rejection for TB culture samples. A single GeneXpert sample was rejected because of insufficient volume. Rejections of specimens were consistently communicated to submitting clinic. However, there was no evidence of receipt of another sample for the requested tests.

Test interruption {#sec014}
-----------------

HIV viral load and GeneXpert testing did not experience service interruptions ([Table 4](#pone.0230532.t004){ref-type="table"}). TB culture and EID testing was repeatedly interrupted. Mycobacteria growth indicator tubes were frequently unavailable. Even if a back-up laboratory was assigned, the stock out was a national problem and only the Lowenstein-Jensen culture method was available. EID testing was interrupted by both reagent stock out (HIV qualitative control, 2 months) and equipment downtime (Abbott2000RT, 7 days, March 2019; Abbott2000SP, 15 days, September 2019).

10.1371/journal.pone.0230532.t004

###### Stock out, equipment down time, and service interruption days APHI, January to September 2019.
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  Tests          2019                                                                                           
  -------------- ------ --- ------------- ------------- ------------- ------------- ------------- ------------- -------------
  Viral load     0      0   0             0             0             0             0             0             0
  EID            0      0   Yes/26 days   Yes/28 days   0             0             0             0             Yes/15 days
  TB culture     0      0   0             MGIT yes/15   MGIT yes/31   MGIT yes/31   MGIT yes/31   MGIT yes/31   MGIT yes/31
  GeneXpert TB   0      0   0             0             0             0             0             0             0

EID: exposed infant diagnosis; MGIT: Mycobacteria growth indicator tube; TB: tuberculosis.

Genexpert error rates and TB culture contamination rates {#sec015}
--------------------------------------------------------

In the Amhara Public Health Institute, the error rate was used as a quality indicator to follow TB GeneXpert tests and contamination rate was used to follow TB culture. Both of the indicators were targeted to be less than 5%. Interestingly, all of the monthly error rates and contamination rates reported were within the targeted limit that had been established by the institute. TB culture contamination rate increased from March (2.8%) to June (5.0%) in 2019. Then, it was continuously decreased up to the end of August 2019 (1.0%). Regarding TB GeneXpert, the average error rate over the study period was 1.4%, with monthly error rates ranging 0% - 4.0% (Figs [1](#pone.0230532.g001){ref-type="fig"} and [2](#pone.0230532.g002){ref-type="fig"}).

![Trend of GeneXpert error rates in APHI from January to September 2019.](pone.0230532.g001){#pone.0230532.g001}

![Trend of TB culture contamination rates in APHI from January to September 2019.](pone.0230532.g002){#pone.0230532.g002}

Performance of proficiency testing {#sec016}
----------------------------------

The laboratories participated in April 2019 in the international PT from Oneworld Accuracy, which is an approved PT provider. All of the assays in the PT program met the minimum requirement for quality performance. Specifically, viral load, EID and GeneXpert had 100% performance as evaluated in April 2019. TB culture PT performance was 80%, which fulfilled the minimum passing mark.

Turnaround times {#sec017}
----------------

The majority of the tests conducted for TB related laboratory diagnosis had acceptable TAT. TB culture tests were released within the targeted TAT except in September 2019. Minimum and maximum average TAT was 43.3 and 65.7 days documented in February and August 2019, respectively. TB GeneXpert tests were consistently completed within the target TAT in March, June and July 2019. However, the average TAT across the study period was 2.3 days with a range of 1.0 to 4.0 days.

Regarding the viral load tests, the average TAT over the study period was 16.5 days, ranging 7.6 to 24.1 days. The TAT improved from January to July 2019 except May 2019 with 18.6% of requested viral load tests out of the defined TAT. Furthermore, the TAT was longer in August and in September 2019 12.6%, and 81.5% of viral load tests were delayed, respectively. EID tests were not done in January, March, and April. Approximately, 35% of the EID tests were delayed in May 2019 with increasing delays occurring throughout the remainder of the study period. During the 9 month reporting period, the EID had a minimum TAT of 23.4 days (February 2019) and maximum TAT of 45.6 days (May 2019) (Tables [5](#pone.0230532.t005){ref-type="table"} and [6](#pone.0230532.t006){ref-type="table"}).

10.1371/journal.pone.0230532.t005

###### Proportion of out of turnaround time of patient results in APHI reference laboratories, January to September 2019.
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  Tests              2019                                                   
  ------------------ ------ ------ ----- ----- ------ ------ ------ ------- -------
  Viral load (%)     15.0   12.8   0.0   0.0   18.6   0.0    0.0    12.6    81.5
  EID (%)            ND     18.4   ND    ND    34.5   50.6   67.4   100.0   100.0
  TB culture (%)     2.1    3.4    0.0   0.0   1.6    0.0    0.0    0.0     10.8
  GeneXpert TB (%)   0.0    0.0    0.0   3.7   6.8    15.4   7.3    6.8     6.8

EID: exposed infant diagnosis; ND: not done; TB: tuberculosis.

10.1371/journal.pone.0230532.t006

###### Average monthly TAT of HIV and TB related laboratory tests, APHI, January to September 2019.
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  Tests               2019                                                           
  ------------------- ------ ------ ------ ------ ------ ------ ------ ------ ------ ------
  Viral load/ day     12.7   13     7.6    8.9    21.8   21.9   19.2   19.1   24.1   16.5
  EID/day             24     23.4   ND     ND     45.6   30.6   24.3   32.8   29.3   30.0
  TB culture/ day     50     43.3   48.7   49.8   53.4   51.6   63     65.7   62.8   54.3
  GeneXpert TB /day   4.0    3.6    1.0    2.0    2.9    1.6    1.6    2      2.3    2.3

EID: exposed infant diagnosis; ND: not done; TB: tuberculosis.

Discussion {#sec018}
==========

In this study, the overall specimen rejection rate was 0.43%. Specifically, it was 1.14% for TB culture and 0.43% for viral load tests from January to September 2019. Surprisingly, high monthly sample rejection was documented for TB culture and viral load in September 2019 with 5.3% and 2.4% rejection rates respectively. Those findings were higher compared to the 2% monthly quality indicator target established by the institute. Also, the finding is higher than the specimen rejection of 0.26% reported by Cao et al in Huston, United States \[[@pone.0230532.ref016]\]. This leads to a high rate of repeat specimen collection, delay in result availability and high rate of specimen/ test abandonment \[[@pone.0230532.ref017], [@pone.0230532.ref018]\]. It compromise patient safety, waste resources, patient discomfort, and potential patient complications especially if there are critical values \[[@pone.0230532.ref019]--[@pone.0230532.ref021]\]. There was no evidence of repeat collection of another sample for the requested tests. Hence, the laboratory should proactively take actions such as training of sample collectors on how to collect sufficient samples and process centrifugation of collected samples, and use appropriate sample collection containers in order to avoid rejection of samples referred to the institute from peripheral facilities in Amhara region since our data support that nearly half (46.1%) of the rejected specimens due to centrifugation problem and 40.9% because of use of wrong specimen containers.

Without reliable, affordable, and portable devices, regular testing remains a challenge \[[@pone.0230532.ref022]\]. In this study, the EID testing service was continuously interrupted for a period of over two months in addition to the interruption of liquid TB culture (MGIT method) testing. The reagent stock out was a national problem and identifying a back-up laboratory was not effective as none of the laboratories were able to obtain the reagents. Testing centers in Ghana had a shortage of EID reagents \[[@pone.0230532.ref023]\]. Equipment down time was also a major cause of test interruptions. Studies in Addis Ababa Ethiopia and in Malawi also revealed that the major reported factors affecting the provision of quality services were a shortage of resources and equipment failure \[[@pone.0230532.ref024], [@pone.0230532.ref025]\]. As a quality improvement plan, the laboratory could reduce interruption of tests through rapid implementation of equipment maintenance service agreements, making back up referring laboratory functional, and building maintenance workshop when there is equipment failure. In addition, the institute should establish a system for international assistance for advanced laboratory test reagents and supplies when these items are stocked out at national level.

An efficient laboratory workflow ensures that specimens received in the laboratory are tested within the established laboratory turnaround time and results are returned to health care providers and their patients on time. However, specimen backlogs can occur when there is suboptimal workflow in the laboratory network as the result of poor sample quality, reagent or consumable stock out, and equipment breakdown \[[@pone.0230532.ref026]\]. In this study, the TAT of viral load and EID tests were longer than target limits. About 82% of viral load tests and 100% of the EID tests had out of targeted TAT in September 2019. It was higher than a study done in Myanmar where long TAT was observed in 69% of the participants \[[@pone.0230532.ref027]\], and in Kenya and Malawi where EID and viral load tests lasted average TAT of 24.7 and 8 days, respectively \[[@pone.0230532.ref028], [@pone.0230532.ref029]\]. This could be due to stock-outs of reagents and maintenance issues with the automated PCR testing equipment since our data showed reagent stock out of EID in about 54 days and equipment down time for a total of 22 days in the nine months from January to September 2019. In general, the TAT for viral load and EID showed increasing delays up to the end of September 2019.

Limitations {#sec019}
-----------

Percentage of incorrect laboratory test reports and notification of critical results were not evaluated since we didn't have these data during the study period. Similarly, we didn't measure IQC performance in the analytical phase of testing process.

Conclusions {#sec020}
===========

In this study, there were high rates of TB culture and viral load specimen rejection due to centrifugation problems and the use of wrong specimen containers. Equipment downtime and reagent stock out were the main causes of EID test interruption. The trend of TAT of viral load and EID tests were longer than the targeted average TAT. Hence, training of sample collectors, functional equipment maintenance systems and improved supply chain management are recommended for continuous quality improvement in addition to conducting a large scale study to identify more factors.

The authors would like to acknowledge the Amhara Public Health Institute for cooperation to use the database and review records.
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• Where was 0.26% reported by Cao et al., in line 197 and modify sample recollection with repeat specimen collection in line 197 and any other place recollection of sample appear in text

• In line 199, include compromise before patient safety and modify resources wastes to waste resources.

• In line 203 replace sample collectors with Phlebotomy and do so through text and replace sole in line 205 with avoid and include nearly half in line 2016 before 46.1% and include specimen before containers in line 207

• In line 209 include for a period of after interrupted and remove in the study after month.

• The sentence in line 212 to 213 require modification and done after studies should be expunge

• In line 222 replace is with was and in line 223 remove and replace observed or recorded with seen and line 224 that the should be replace with where and include period after months in 227.

Conclusion:

Effect on necessary correction pointed out in discussion in conclusion include specimen in line 231 before container and time after down and phlebotomy in line 233 to replace samples collectors and include improved in line 234 after and before supply.

Tables and Figures

• Table 1 Epert TB should read GeneXpert TB and include Abbreviations Definition under table

• Table 2 inlcude n(%) for each test and include Abbreviations and Definition

• Include figure title under each Chart for Line Graph for Fig 1 and Fig 2 respectively

Finally,authors may wish to consider consulting an English expert for proof reading and Plos one Journal Editor may wish to carry our independent plagiarism check on the manuscript.

Reviewer \#2: This paper describes performance measures for TB culture, TB rifampicin resistance (RR) testing using GeneXpert, HIV viral load testing, and early infant diagnosis (EID) of HIV testing. This is one of the first papers to assess quality indicators for laboratory testing in Ethiopia. The gaps and successes in laboratory testing in Ethiopia outlined in this paper offer several important contributions to the literature and can guide more effective testing processes in Ethiopia and other similar settings.

The manuscript requires re-organization and editing to clarify the results and be more accessible to non-specialists. By section, my suggestions are as follows:

Introduction

1\. Lines 54-58: You mention that "recommended quality indicators for the post-analytical phase are turnaround time (TAT), the percentage of incorrect laboratory test reports, and notification of critical results," yet you do not measure or report on incorrect laboratory results or notification of critical results. Do you have these data? If not, consider adding to the limitations.

2\. Lines 59-62: Confusing sentence, consider revising

3\. Lines 68-71: The statistics for MRD/RR-TB and ART use seem out of place here and hard to contextualize in terms of laboratory testing requirements. Would be more useful to know -- at a national level -- how many patients require each of these tests annually.

Methods

4\. Line 111: Should be "Oneworld Accuracy", please ensure correct spelling and capitalization. Also suggest citing

5\. Line 93: GeneXpert spelled incorrectly.

6\. Lines 89: How does the indicator "test interruption" differ from equipment downtime and stock out?

7\. Line 95: Unclear to reader what "Besides, reagent stock out status was set to be zero" means.

8\. Line 102: Suggest rephrasing to say, "sample received 5+ days after collection..."

9\. Line 104, "old" plasma samples -- please quantify what how old is "old"

10\. Lines 109-114, please describe in more detail what proficiency testing entails.

u

11\. Lines 112-118: How were these targets (PT 80%, contamination \<5%, error \<5%, TAT for each test) established?

Results

1\. The presentation of results is difficult to follow. I would suggest presenting the all of results for each test separately and then moving on to the next test, keeping the same format and organization for the presentation of results of each test. For example, discuss TB culture first and talk about:

a\. Pre-examination indicators:

i\. total number of samples for culture TB

ii\. rejection rate for culture TB and reasons for rejection

b\. Examination phase indicators:

i\. Test interruption for culture TB & reasons

ii\. Error/contamination rates and reasons for culture TB

c\. Post examination phase indicators:

i\. TAT for culture TB

Then repeat this sequence of results presentation for GeneXpert, EID, and VL.

2\. The inclusion of data per month complicates the results, without adding much benefit, since there does not seem to be a temporal trend in indicators. I would suggest removing references to months when specific rates were achieved. Instead, the results could be simplified by first giving the average across the entire study period and then giving the low to high range, rather than specify the value per month.

a\. For example, Lines 165-167 could be simplified to "Regarding TB GeneXpert, the average error rate over the study period was XX%, with monthly error rates ranging from 0%-4%."

3\. No examination phase measures for HIV viral load testing are discussed.

4\. average TAT across the study period was not specified for each test, rather, monthly rates were given, which unnecessarily complicates the results.

5\. TAT for GeneXpert RR tests are not specified, other than "good".

6\. Tables 4 and 5. What is the difference between turnaround time and waiting time?

7\. Table 4: I'd suggest a title that makes it clearer that the numbers presented are rates of samples that achieved TAT targets. As is, that is not clear.

Discussion

• The authors miss an opportunity to discuss recommendations to address the gaps that their data highlights. The only recommendation offered discusses the need for training to address sample rejection issues (lines 202-206). While important, this will not help with machine down, stockouts and long turnaround times -- what can be done to improve indicators for these?

• Please discuss the 2 months where no EID tests were conducted -- what happened to the EID samples during the period: were they sent to other labs? Were they held on to and processed once the machine was repaired and reagents replenished -- if so, this could explain the increased sample volume and TAT observed in May?

• Line 221-222: "About 82% of viral load tests and 100% of the EID tests had an average TAT of 45.6 days in September 2019."

• Suggest adding a limitations section.

General comments

1\. Please define all acronyms at first use. Some that were not accurately defined include: MDR/RR-TB (line 68); IFRR/RRF (line 96); DRTB (line 98), MGIT (line 152), LJ culture (line 154)

2\. Please be sure to write GeneXpert with correct capitalization pattern

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0230532.r002

Author response to Decision Letter 0

14 Dec 2019

\'Response to Reviewers\'.

Dear editor, thank you so much for mailing the comments. We would like to thank the reviewer's, really well appreciated critics and we learn a lot from the review, and also our work now has been improved much from their comments. The following is our point by point response:

Journal Requirements:

In the ethics statement in the manuscript and in the online submission form, please provide additional information about the patient records/samples used in your retrospective study. Specifically, please ensure that you have discussed whether all data/samples were fully anonymized before you accessed them and/or whether the IRB or ethics committee waived the requirement for informed consent. If patients provided informed written consent to have data/samples from their medical records used in research, please include this information.

Response: thank you, now detailed ethics statement has been included in the manuscript and in the online submission form.

Reviewers\' comments:

Reviewer \#1:

Abstract:

Background:

• The focus of this study is continuous quality improvement (CQI) assessment using specific laboratory indicators but information on CQI not provided.

Response: Thank you, now it has been provided in the revised manuscript

• The established target was your laboratory specific and should be made clear as such in line 30 including specific target for each quality indicators.

Response: Thank you, it has been made clear now since include specific target for each quality indicators in table 1 of the new version manuscript. But, to include in the abstract part it became more detailed and out of word limit. So, table 1 and description in the method part is enough.

• Replace long waiting time with TAT and effect same correction throughout the text for uniformity and consistency of terminology.

Response: thank you, it has been replaced throughout the text

Methods:

• Line 26 through 30 should contain information of number of facilities and level of health care if such data is available. This would help for another level of analysis to improve the work further. How was the data collected, reviewed cleaned and analyzed was not stated.

Response: thank you, now we have stated how the data was collected, reviewed cleaned and analyzed. However, information of number of facilities and level of health care data was not available to include as suggested.

• Line 38 stated that ''EID had a long waiting time in September 2019''. What specific time are you referring to?. Include the exact data for the TAT.

Response: thank you, now it has been described. The specific time was 29.3 days as described in the new version manuscript.

Introduction:

• The authors may wish to consider this statement Continuous quality improvement (CQI) is a useful objective tool to improve processes and services and linking it with line 45 through 48 and ensuring effective flow and synchronization. Pre-analytical error and Post-analytical error data are abundant and well documented and would be important to include them in the introduction.

Response: : thank you, pre-analytical error and Post-analytical error data has been included them in the introduction

• Line 54 replace ''equipment down'' with equipment down time and do same throughout text and include internal quality control (IQC) after proficiency testing in line 55.

Response: thanks, now it has been corrected as the reviewer's advice.

• Replace "has been magnified more'' with would become magnified in line 66 and expunge such and of in line 74 and 76 respectively.

Response: thanks, now it has been corrected as the reviewer's advice.

Materials and Methods:

Authors may wish to consider subheading using the following guide for easy readability:

1\. Study Design and ensure the actual study design was well stated since data was retrospective

Response: thanks, now it has been corrected

2\. Setting should be well describe including longitude and latitude of the study facility

Response: Now it has been well described as shown in the setting part of the method section

3\. Data Collection

Response: thanks, now it has been revised

4\. Quality indicators and objective of each

Response: thanks, now it has been revised and we include it together with data collection part

5\. Data review, cleaning and data Analysis

Response: thanks, now it has been revised

6\. Ethical Approval or Ethical Consideration

Response: thanks, now it has been revised

7\. Table for quality indicator and threshold or target for the laboratory

Response: Thank you, now the table has been included as the reviewer's advice.

Line 91 replace maintained with repair or fix and do same for gexpert with GeneXpert in line 93.

Response: thanks, now it has been corrected

Please define all abbreviations such as RR, RRF, RRF and DBS in text before they can be use.

Response: thanks, now it has been revised

What of Internal quality control monitoring threshold or target for qualitative data such as viral load testing?

Response: Thanks, it is 100%. It is described in table 1 of the new version manuscript.

Results Section:

• You may wish to consider including characteristics of facilities and various level of health cares including ownership (private and public) in the result section. Include percentage in parenthesis for each absolute number from lie 132 through 137.

Response: Thanks, now we have included percentage in parenthesis for each absolute number from line 132 through 137. However, we couldn't get data for characteristics of health facilities to include as the reviewers recommendation.

• Ensure you do not repeat results in tables for example use term like about half or close to half or one-third etc.

Response: Thank you for the comment; it has been revised according to the reviewers advice.

• Between line 160 and 167 ensure that text are presented as they are arrange in heading and remove was in line 164 after rate. Replace March (2.8%) to June (5.0%) in 2019 with what you have in line 164.

Response: Thank you, now corrections have been made based on the reviewer comments.

• Please replaced waiting time with TAT with waiting time throughout text see Line 175 through 190.

Response: Thank you, now waiting time has been replaced with TAT in the revised version manuscript.

• What of GeneXpert Data?

Response: Now, we specified in the result section under TAT in addition to table 5

• In line 179 replace interestingly with However and expunge was in 181 after TAT, include 2019 after May in line 181 and same in line 189 after February.

Response: Thank you, now it has been corrected

Discussion:

• Authors may wish to consider major findings summary as the first paragraph and discussion of results chronologically as presented in result section in next paragraphs thereafter

Response: Thanks, now we add summary of results in the first paragraph of the discussion section as the reviewer's advice.

• Include period of months in line 193 and replace This finding and is in line 195 with Those findings and was.

Response: Now, it has been corrected

• Where was 0.26% reported by Cao et al., in line 197 and modify sample recollection with repeat specimen collection in line 197 and any other place recollection of sample appear in text

Response: Thanks, it was in Huston, United States. And recollection has been modified based on the reviewer's advice.

• In line 199, include compromise before patient safety and modify resources wastes to waste resources.

Response: Thank you very much; it really helps us to improve our paper. And it has been modified accordingly.

• In line 203 replace sample collectors with Phlebotomy and do so through text and replace sole in line 205 with avoid and include nearly half in line 2016 before 46.1% and include specimen before containers in line 207

Response: Thank you; all recommendations have been corrected in the new version manuscript except Phlebotomy that it better to use as it's, because the term phlebotomy more related to blood collections, but in our study, we have more than blood sample like sputum.

• In line 209 include for a period of after interrupted and remove in the study after month.

Response: Thank you; now it has been modified

• The sentence in line 212 to 213 require modification and done after studies should be expunge

Response: Thank you; now it has been modified

• In line 222 replace is with was and in line 223 remove and replace observed or recorded with seen and line 224 that the should be replace with where and include period after months in 227.

Response: Now, it has been corrected

Conclusion:

Effect on necessary correction pointed out in discussion in conclusion include specimen in line 231 before container and time after down and phlebotomy in line 233 to replace samples collectors and include improved in line 234 after and before supply.

Response: Now, it has been corrected

Tables and Figures

• Table 1 Epert TB should read GeneXpert TB and include Abbreviations Definition under table

Response: Now, it has been corrected

• Table 2 inlcude n(%) for each test and include Abbreviations and Definition

Response: Response: Now, it has been corrected

• Include figure title under each Chart for Line Graph for Fig 1 and Fig 2 respectively

Response: Thank you for the comment. The journal requirement describes to provide figures in separate and title to include in the main manuscript. That is why we didn't put under each figure. The editor may put it under the graph during publication.

Reviewer \#2:

Introduction

1\. Lines 54-58: You mention that "recommended quality indicators for the post-analytical phase are turnaround time (TAT), the percentage of incorrect laboratory test reports, and notification of critical results," yet you do not measure or report on incorrect laboratory results or notification of critical results. Do you have these data? If not, consider adding to the limitations.

Response: Thank you, comment accepted and it has been described as limitation at the end of the discussion part

2\. Lines 59-62: Confusing sentence, consider revising

Response: Thank you, now it has been revised to avoid the confusion.

3\. Lines 68-71: The statistics for MRD/RR-TB and ART use seem out of place here and hard to contextualize in terms of laboratory testing requirements. Would be more useful to know -- at a national level -- how many patients require each of these tests annually.

Response: Thank you. The statistics described was to give background information how much of the patients suffer from HIV and TB related health problems at national level including our setting. All of the listed statistics require quality assured laboratory results. So, we believe this information is important and has not been deleted.

Methods

4\. Line 111: Should be "Oneworld Accuracy", please ensure correct spelling and capitalization. Also suggest citing

Response: Thank you, now it has been corrected and cited.

5\. Line 93: GeneXpert spelled incorrectly.

Response: Thank you, now it has been corrected

6\. Lines 89: How does the indicator "test interruption" differ from equipment downtime and stock out?

Response: Thank you, it differs because the lab uses back up referring laboratories to avoid test interruption when there is either equipment downtime or stock out.

7\. Line 95: Unclear to reader what "Besides, reagent stock out status was set to be zero" means.

Response: now it has been modified. It means no reagent stock out was set as a quality indicator by APHI.

8\. Line 102: Suggest rephrasing to say, "sample received 5+ days after collection..."

Response: Thank you, now it has been rephrased as the reviewer's advice

9\. Line 104, "old" plasma samples -- please quantify what how old is "old"

Response: Thanks, it was said old plasma samples if it was delayed \>5 days after collection when transported to APHI at 2-8oC. Now it has been included in the new manuscript.

10\. Lines 109-114, please describe in more detail what proficiency testing entails.

Response: Now it has been more entailed and included in the new version manuscript.

11\. Lines 112-118: How were these targets (PT 80%, contamination \<5%, error \<5%, TAT for each test) established?

Response: Thanks, now it has been included in table 1 of the new version manuscript

Results

1\. The presentation of results is difficult to follow. I would suggest presenting the all of results for each test separately and then moving on to the next test, keeping the same format and organization for the presentation of results of each test. For example, discuss TB culture first and talk about:

a\. Pre-examination indicators:

i\. total number of samples for culture TB

ii\. rejection rate for culture TB and reasons for rejection

b\. Examination phase indicators:

i\. Test interruption for culture TB & reasons

ii\. Error/contamination rates and reasons for culture TB

c\. Post examination phase indicators:

i\. TAT for culture TB

Then repeat this sequence of results presentation for GeneXpert, EID, and VL.

Response: Thank you for the comments. But when we tried to rearrange based on the suggested sequence of results, it became more complicated and difficult to describe repeated quality indicators. So, we prefer the current sequence of results presentation.

2\. The inclusion of data per month complicates the results, without adding much benefit, since there does not seem to be a temporal trend in indicators. I would suggest removing references to months when specific rates were achieved. Instead, the results could be simplified by first giving the average across the entire study period and then giving the low to high range, rather than specify the value per month.

a\. For example, Lines 165-167 could be simplified to "Regarding TB GeneXpert, the average error rate over the study period was XX%, with monthly error rates ranging from 0%-4%."

Response: now it has been simplified based on the reviewer's advice.

3\. No examination phase measures for HIV viral load testing are discussed.

Response: Thank you, it has been already discussed in the result section under proficienc testing performance stating "All of the tests participated in the PT program qualified the minimum requirement that the passing mark was 80%. Specifically, viral load, EID and GeneXpert had 100% performance as evaluated in April 2019". But IQC was not discussed since we didn't evaluate it and we put as limitation in the new version manuscript.

4\. average TAT across the study period was not specified for each test, rather, monthly rates were given, which unnecessarily complicates the results.

Response: Thank you, now it has been included in the result section and in table 5.

5\. TAT for GeneXpert RR tests are not specified, other than "good".

Response: Now, it has been specified in the new version manuscript

6\. Tables 4 and 5. What is the difference between turnaround time and waiting time?

Response: Thank you so much, comments help us to improve the paper. Table 4 describes the proportion of out of TAT patient results in APHI, and Table 5 describes the average TAT of tests. In the new version manuscript, the title of table 4 has been modified as "Proportion of out of turnaround time of patient results in APHI reference laboratories, January to September 2019"

7\. Table 4: I'd suggest a title that makes it clearer that the numbers presented are rates of samples that achieved TAT targets. As is, that is not clear.

Response: Thank you the title now has been cleared. Yes, rates of samples that achieved TAT targets

Discussion

• The authors miss an opportunity to discuss recommendations to address the gaps that their data highlights. The only recommendation offered discusses the need for training to address sample rejection issues (lines 202-206). While important, this will not help with machine down, stockouts and long turnaround times -- what can be done to improve indicators for these?

Response: Thank you so much, very important view and help to improve our work. Now, recommendations have been included to address the gaps highlighted.

• Please discuss the 2 months where no EID tests were conducted -- what happened to the EID samples during the period: were they sent to other labs? Were they held on to and processed once the machine was repaired and reagents replenished -- if so, this could explain the increased sample volume and TAT observed in May?

Response: Thank you, the 2 months EID interruption was due to the national stock out occurred in Ethiopia that all of the labs in Ethiopia were not able to test EID. It was impossible to send samples to other laboratories. In addition, equipment was failed in April for seven days as explained in the result section. Maintenance was done after that. No, these issues have been explained in the discussion section.

• Line 221-222: "About 82% of viral load tests and 100% of the EID tests had an average TAT of 45.6 days in September 2019."

Response: Thank you so much, now it has been corrected as "About 82% of viral load tests and 100% of the EID tests had out of targeted TAT in September 2019".

• Suggest adding a limitations section.

Response: thanks, now limitation section has been included in the new version manuscript.

General comments

1\. Please define all acronyms at first use. Some that were not accurately defined include: MDR/RR-TB (line 68); IFRR/RRF (line 96); DRTB (line 98), MGIT (line 152), LJ culture (line 154)

Response: thanks, now it has been revised

2\. Please be sure to write GeneXpert with correct capitalization pattern

Response: thanks, now it has been revised
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4 Feb 2020

PONE-D-19-30524R1

Evaluation of continuous quality improvement of tuberculosis and HIV diagnostic services in Amhara public health institute, Ethiopia

PLOS ONE

Dear Mr Shiferaw,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

The revisions address the reviewers comments regarding content but the manuscript needs further editing for language.  Attached is a copy of the submitted revision, highlights many of the grammatical issues that need correction. 

==============================

We would appreciate receiving your revised manuscript by Mar 20 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Evelyn Byrd Quinlivan, MD

Academic Editor

PLOS ONE

Additional Editor Comments (if provided):

The manuscript addresses the reviewers comments. The manuscript should be heavily edited for grammar prior to publication.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: N/A

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: After reviewing the responses of the authors during the second stage of this review process i have the following comments that would guide the Academic editor on the final decision on the work.

1, The authors have painstakingly addressed all issues and comments raised during the first review outcomes

2\. All modification and correction have been effected thereby improving the work further for publication

3\. Authors have also reviewed each comments and concerns raised and provided useful explanation on various modification/correction made or why modification may be possible is few cases.

4\. The Academic Editor may wish to do independent Plagiarism check before acceptance and final publication

Reviewer \#2: The revised manuscript is much clearer, with reviewer comments adequately addressed. I do recommend a final review by a native English speaker to improve the fluency of the writing.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

###### 

Submitted filename: PONE-D-19-30524_R1 ebq.pdf

###### 

Click here for additional data file.

10.1371/journal.pone.0230532.r004

Author response to Decision Letter 1

5 Feb 2020
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PONE-D-19-30524R2

Dear Dr. Shiferaw,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.
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